Neuromuscular blockade: What was, is and will be

Acta Anaesthesiologica Belgica

Volumn 65, Issue 4, 2014, Pages 151-159

  Schepens, T ^a   Cammu, G ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b OLV HOSPITAL   (Belgium)

Author keywords

Diaphragm; Neuromuscular block; Neuromuscular blocking agents; Nicotinic acetylcholine receptor; Sugammadex

Indexed keywords

CHOLINESTERASE INHIBITOR; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT; SUGAMMADEX;

DRUG EFFECTS; HUMAN; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

CHOLINESTERASE INHIBITORS; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR JUNCTION; SYNAPTIC TRANSMISSION;

EID: 84921747806     PISSN: 00015164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. rd edn., London, Wright. 1990.
2. Fagerlund M.J., Eriksson L.I., Current concepts in neuromuscular transmission, BR. J. ANAESTH., 103, 108-114, 2009.
3. Brady J. E., Sun L. S., Rosenberg H., et al., Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005, ANESTH. ANALG., 109, 1162-1166, 2009.
4. Association of Anaesthetists of Great Britain and Ireland. Suspected anaphylactic reactions associated with anaesthesia, ANAESTHESIA, 64, 199-211, 2009.
5. Kroigaard M., Garvey L. H., Gillberg L., Scandinavian Clinical Practice Guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia, ACTA ANAESTHESIOL. SCAND., 51, 655-670, 2007.
6. Johansson S. G., Florvaag E., Oman H., et al., National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study, ALLERGY, 65, 498-502, 2010.
7. Florvaag E., Johansson S. G., Irgens A., de Pater G. H., IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market, ALLERGY, 66, 955-960, 2011.
8. Laxenaire M. C., Mertes P. M., Anaphylaxis during anaesthesia. Results of a two-year survey in France. Groupe d'Etudes des Réactions Anaphxlactoides Peranesthésiques, BR. J. ANAESTH., 87, 549-558, 2001.
9. Reitter M., Petitpain N., Latarche C., et al, Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis, ALLERGY, 69, 954-959, 2014.
10. Miller R., Will succinvlcholine ever disappear?, ANESTH. ANALG., 98, 1674-1675, 2004.
11. Jooste E., Klafter F., Hirshman C. A., Emala C.W., A mechanism for rapacuromum-induced bronchospasm: M2 muscarinic receptor antagonism, ANESTHESIOLOGY, 98, 906-911, 2003.
12. Naguib M., Kopman A. F., Ensor J.E., Neuromuscular monitoring and postoperative residual. curarisation: a meta-analysis, BR. J. ANAESTH., 98, 302-316, 2007.
13. Debaene B., Plaud B., Dilly M. P., et al, Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action, ANESTHESIOLOGY, 98, 1042-1048, 2003.
14. Baillard C., Gehan G., Reboul-Marty J., et al, Residual curarization in the recovery room after vecuronium, BR. J. ANAESTH., 84, 394-395, 2000.
15. Cammu G., De Witte J., De Veylder J., et al., Postoperative residual paralysis in outpatients versus inpatients, ANESTH. ANALG., 102, 426-429, 2006.
16. Arain S. R., Kern S., Ficke D. J., et al., Variability of duration of action of neuromuscular-blocking drugs in elderly patients, ACTA ANAESTHESIOL. SCAND., 49, 312-315, 2005.
17. Waud B. E., Waud D. R., The relation between tetanic fade and receptor occlusion in the presence of competitive neuromuscular block, ANESTHESIOLOGY, 35, 456-464, 1971.
18. Berg H., Roed J., Viby-Mogensen J., et al, Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium, ACTA ANAESTHESIOL. SCAND., 41, 1095-1103, 1997.
19. Arbous M.S., Meursing A. E., van Kleef J. W., et al., Impact of anesthesia management characteristics on severe morbidity and mortality, ANESTHESIOLOGY, 102, 257-268, 2005.
20. Cammu G. V., Smet V., De Jongh K., et al., A prospective, observational study comparing postoperative residual curarisution and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery, ANAESTH. INTENSIVE CARE, 40, 999-1006, 2012.
21. Grosse-Sundrup M., Henneman J. P., Sandberg W. S., et al., Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study, BMJ., 345, e6329, 2012.
22. Eriksson L. I., Reduced hypoxic chemosensitivity in partially paralysed man. A new property of muscle relaxants?, ACTA ANAESTHESIOL. SCAND., 40, 520-523, 1996.
23. Eikermann M., Groeben H., Hüsing J., et al., Accelerometry of adductor pollicis muscle predicts recovery of respiratory function from neuromuscular blockade, ANESTHESIOLOGY, 98, 1333-1337, 2003.
24. Sundman E., Witt H., Olsson R., et al, The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: phalangeal video-radiography and simultaneous manometry after atracurium, ANESTHESIOLOGY, 92, 977-984, 2000.
25. Kopman A. F., Yee P. S., Neuman G. G., Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers, ANESTHESIOLOGY, 86, 765-771, 1997.
26. Kumar G.V., Nair A. P., Murthy H. S., et al., Residual neuromuscular blockade affects postoperative pulmonary function, ANESTHESIOLOGY, 117, 1234-1244, 2012.
27. Grayling M., Sweeney B. P., Recovery from neuromuscular blockade: a survey of practice, ANAESTHESIA, 62, 806-809, 2007.
28. Videira R. L., Vieira J. E., What rules of thumb do clinicians use to decide whether to antagonize nondepolarizing neuromuscular blocking drugs?, ANESTH. ANALG., 113, 1192-1196, 2011.
29. Baillard C., Clec'h C., Catineau J., et al., Postoperative residual neuromuscular block: a survey of management, BR. J. ANAESTH., 95, 622-626, 2005.
30. Kirkegaard H., Heier T., Caldwell J. E., Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block, ANESTHESIOLOGY, 96, 45-50, 2002.
31. Kopman A. F., Zank L. M., Ng J., et al., Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory?, ANESTH. ANALG., 98, 102-106, 2004.
32. Fuchs-Buder T., Meistelman C. Alla F., et al., Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine, ANESTHESIOLOGY, 112, 34-40, 2010.
33. Cheng C. R., Sessler D. I., Apfel C. C., Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? ANESTH. ANALG., 101, 1349-1355, 2005.
34. Delia Rocca G., Pompei L., Pagan D. E., et al, Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study, ACTA ANAESTHESIOL. SCAND., 57, 1138-1145, 2013.
35. De Boer H. D., Driessen J. J., Marcus M. A., et al., Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study, ANESTHESIOLOGY, 107, 239-244, 2007.
36. De Kam P. J., Grobara P., Dennie J., et al., Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia, CLIN. DRUG INVESTIG., 33, 545-551, 2013.
37. Plaud B., Debaene B., Donati F., et al, Residual paralysis after emergence from anesthesia, ANESTHESIOLOGY, 112, 1013-1022, 2010.
38. Ledowski T., Falke L., Johnston F., et al, Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: Sugammadex, neostigmine or no reversal, EUR. J. ANAESTHESIOL., 31, 423-429, 2014.
39. Dubois P.E., Mulier J. P., A review of the interest of sugammadex for deep neuromuscular blockade management in Belgium, ACTA ANAESTHESIOL. BELG., 64, 49-60, 2013.
40. Martini C. H., Boon M., Bevers R. F., et al., Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block, BR. J. ANAESTH., 112, 498-505, 2014.
41. Dubois P. E., Putz L., Jamart J., et al., Deep neuromuscular block improves surgical conditions during laparoscopic hysterectomy: A randomised controlled trial, EUR. J. ANAESTHESIOL., 31, 430-436, 2014.
42. De Boer H. D., van Esmond J., Booij L. H., et al., Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy, PAEDIATR. ANAESTH., 19, 1226-1228, 2009.
43. Bisschops M.M., Holleman C., Huitink J. M., Can sugammadex save a patient in a simulated 'cannot intubate, cannot ventilate' situation?, ANAESTHESIA, 65, 936-941, 2010.
44. Telgarsky B., Stacey M., Sugammadex and the cannot intubatelcannot ventilate scenario in patients with predicted difficult airway(1). Letter 2, BR. J. ANAESTH., 109, 459-460, 2012.
45. Cammu G., Van Vlem B., van den Heuvel M., et al., Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment, BR. J. ANAESTH., 109, 382-390, 2012.
46. Cammu G., de Kam P. J., De Graeve K., et al., Repeat dosing of rocuronium 1.2 mg kg-1 after reversal of neuromuscular block by sugammadex 4.0 mg kg-1 in anaesthetized healthy volunteers: a modelling-based pilot study, BR. J. ANAESTH., 105, 487-492, 2010.
47. Godai K., Hasegawa-Moriyama M., Kuniyoshi T., et al, Three cases of suspected sugammadex-induced hypersensitivity reactions, BR. J. ANAESTH., 109, 216-218, 2012.
48. Tsur A., Kalansky A., Hypersensitivity associated with sugammadex administration: a systematic review, ANAESTHESIA, 2014, in press.
49. De Kam P. J., Grobara P., Prohn M., et al., Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects, INT. J. CLIN. PHARMACOL. THER., 52, 227-236, 2014.
50. Kotake Y., Ochiai R., Suzuki T., et al, Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block, ANESTH. ANALG., 117, 345-351, 2013.
51. Van Gestel L., Cammu G., Is the effect of sugammadex always rapid in onset? ACTA ANAESTHESIOL. BELG., 64, 41-47, 2013.
52. Cammu G., de Baerdemaeker L., den Blauwen N., et al., Postoperative residual curarization with cisatracurium and rocuronium infusions, EUR. J. ANAESTHESIOL., 19, 129-134, 2002.
53. Papazian L., Forel J. M., Gacouin A., et al, Neuromuscular blockers in early acute respiratory distress syndrome, N. ENGL. J. MED., 363, 1107-1116, 2010.
54. Cammu G., Cardinael S., Lahousse S., et al, Muscle relaxation does not influence venous oxygen saturation during cardiopulmonary bypass, J. CLIN. ANESTH., 19, 105-109, 2007.
55. Eikermann M., Zaremba S., Malhotra A., et al, Neostigmine but not sagammadex impairs upper airway dilator muscle activity and breathing, BR. J. ANAESTH., 101, 344-349, 2008.
56. Van Beersel D., Cammu G., Van Hecke K., Foubert L., Van De Velde M., The use of sugammadex in a Belgian regional hospital. Proceedings of the research meeting of the Belgian Society of Anesthesia and Resuscitation, ACTA ANAESTHESIOI. BELG., in press.
57. Hoffmann U., Grosse-Sundrup M., Eikermann-Haerter K., et al, Calabadion: A new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents, ANESTHESIOLOGY, 119, 317-325, 2013.
58. Rodiera J., Serradell A., Alvarez-Gomez J. A., et al, The cuff method: a pilot study of a new method of monitoring neuromuscular function, ACTA ANAESTHESIOL. SCAND., 49, 1552-1558, 2005.
59. Jonsson M., Gurley D., Dabrowski M., et al, Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade, ANESTHESIOLOGY, 105, 521-533, 2006.
60. Sakuraba S., Kuwana S.-I., Ochiai R., et al., Effects of neuromuscular blocking agents on central respiratory control in the isolated brainstem-spinal cord of neonatal rat, NEUROSCI. RES., 47, 289-298, 2003.
61. Tassonyi E., Fathi M., Hughes G. J., et al, Cerebrospinal fluid concentrations of atracurium, laudanosine and vecuronium following clinical subarachnoid hemorrhage, ACTA ANAESTHESIOL. SCAND., 46, 1236-1241, 2002.
62. Fuchs-Buder T., Strowitzki M., Rentsch K. et al., Concentration of rocuronium in cerebrospinal fluid of patients undergoing cerebral aneurysm clipping, BR. J. ANAESTH., 92, 419-421, 2004.
63. Jonsson M., Kim C. Yamamoto Y., et al., Atracuriwn and vecuronium block nicotine-induced carotid body chemoreceptor responses, ACTA ANAESTHESIOL. SCAND., 46, 488-494, 2002.
64. Jonsson M. Wyon N., Lindahl S. G. E., et al., Neuromuscular blocking agents block carotid body neuronal nicotinic acetylcholine receptors, EUR. J. PHARMACOL., 479, 173-180, 2004.
65. Fitzgerald R. S., Oxygen and carotid body chemotransduction: the cholinergic hypothesis - a brief history and new evaluation, RESPIR. PHYSIOL., 120, 89-104, 2000.
66. Meyer M. J., Bateman B. T., Kurth T., et al., Neostigmine reversal doesn't improve postoperative respiratory safety, BMJ, 346, 1460-1460, 2013.
67. Paton W. D., Waud D. R., The margin of safety of neuromuscular transmission, J. PHYSIOL., 191, 59-90, 1967.
68. Howkins J., Movement of the diaphragm after operation, LANCET, 2, 85-88, 1948.
69. Bazzy A. R., Donnelly D. F., Diaphragmatic failure during loaded breathing: role of neuromuscular transmission, J. APPL. PHYSIOL., 74, 1679-1683, 1993.
70. Schepens T., Cammu G., Saldien V., et al, Electromyographic activity of the diaphragm during neostigmine-or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: A study in anaesthetised healthy volunteers, EUR. J. ANAESTHESIOL., 31, 2014, in press.